Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · adults in the ICU, requiring respiratory support
1 finding from 1 review
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review
Adverse events Respiratory infection (pneumonia) Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in adverse events Respiratory infection (pneumonia) Nasal mucosa or… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review
Duration of ICU stay · adults in the ICU, requiring respiratory support
1 finding from 1 review
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
Treatment failure (escalation of respiratory therapy to NIV, NIPPV or invasive ventilation) Measured up to 28 days · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in treatment failure (escalation of respiratory therapy to NIV, NIPPV… compared with NIPPV or NIV (low certainty).
1 finding from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with NIPPV or NIV (low certainty).
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
aprepitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
netupitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
Palonosetron (0 RCTs; 0 participants) · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
aprepitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
azasetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review